Table 3.
Exploratory clinical outcomes for thiamine vs placebo
| Outcome | n | Thiamine (n = 24) | Placebo (n = 24) | Mean difference (95% CI)∗ | P† |
|---|---|---|---|---|---|
| Peak GLS, % | 10 | –8.4 (3.4) | –8.0 (3.7) | 0.42 (–0.8, 1.6) | 0.451 |
| LVEF, % | 13 | 39.4 (11.5) | 36.7 (12.7) | –2.8 (–7.0, 1.3) | 0.173 |
| KCCQ overall score | 18 | 60.1 (19.5) | 67.0 (19.6) | –6.8 (13.3, –4.0) | 0.046 |
| KCCQ clinical score | 18 | 69.3 (16.4) | 72.3 (16.9) | –2.9 (–3.3, 9.3) | 0.338 |
| NYHA class, mean (SD) | 19 | 1.79 (0.5) | 1.68 (0.6) | 0.1 (–1.7, 0.4) | 0.414 |
| NYHA class, median (IQR) | 19 | 2 (1.25–2) | 2 (1–2) | N/A | 0.414 |
| NT-proBNP, mean (SD) | 14 | 2805.2 (3099.8) | 3781.1 (4533.9) | –975.8 (–2124.5, 172.7) | 0.113 |
| NT-proBNP, median (IQR) | 14 | 2033.5 (1265.3–3475.0) | 4144.0 (1225.5–4858) | N/A | 0.140 |
Values are mean (standard deviation), unless otherwise indicated. N-terminal pro-brain natriuretic peptide (NT-proBNP) and New York Heart Association (NYHA) class also compared with Wilxocon test because of skew (P = 0.140 and P = 0.414, respectively)
GLS, global longitudinal strain; KCCQ, Kansas City Cardiomyopathy Questionnaire (quality of life); LVEF, left ventricular ejection fraction; N/A, not applicable.
∗
Paired difference.
†
P values for treatment effect from analysis of variance that includes period and carryover effect.